Q-omics provides the consensus-scored JPT1 profile across patient tissues and cancer cell-line models. JPT1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, JPT1 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, JPT1 protein abundance shows 26,108 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, BLCA, and LUAD as cancer lineages where JPT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for JPT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes JPT1 survival associations across molecular data types. JPT1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible JPT1 RNA expression–survival associations across cancer types. High JPT1 expression shows unfavorable associations in KIRC, ACC, MESO, HNSC, LIHC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for JPT1 RNA expression.
This table summarizes JPT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for JPT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. JPT1 shows higher tumor expression in BLCA, LUAD, HNSC, KIRP, THCA and LIHC. The BLCA box plot shows higher JPT1 RNA expression in tumor versus normal tissue (log2 FC = +3.195, t-test p < 0.001).
This table shows molecular features associated with JPT1 in patient tissues and cancer cell lines. In patient samples, JPT1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, JPT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and OVARY.
